Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chia

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
Clinical Breast Cancer|December 26, 2015
Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast CancerSheridan Wilson, Caroline Speers, Scott Tyldesley, et al.
Therapeutic Advances in Medical Oncology|March 24, 2025
Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancerMarya Hussain, Christine Brezden-Masley, Stephen Chia, et al.
Annals of Surgical Oncology|February 13, 2010
Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based seriesPauline T Truong, Mary Lesperance, Karen Hui Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancerIvo A Olivotto, Boon Chua, Sharon J Allan, et al.
Virchows Archiv : an International Journal of Pathology|October 29, 2009
Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five casesMelanie Seal, Christine Wilson, Gregory J Naus, et al.
Pharmaceutical Research|June 11, 2005
Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levelsDawn N Waterhouse, Tetyana Denyssevych, Norma Hudon, et al.
Breast Cancer Research and Treatment|April 30, 2008
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effectsHeather-Jane Au, Kamran Golmohammadi, Tallal Younis, et al.
The Oncologist|February 4, 2012
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancerLindsay Hedden, Susan O'Reilly, Caroline Lohrisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trialStephen Chia, Mark Clemons, Lee-Ann Martin, et al.
Health and Quality of Life Outcomes|December 3, 2013
Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6DPaulos Teckle, Helen McTaggart-Cowan, Kim Van der Hoek, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
Clinical Breast Cancer|December 26, 2015
Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast CancerSheridan Wilson, Caroline Speers, Scott Tyldesley, et al.
Therapeutic Advances in Medical Oncology|March 24, 2025
Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancerMarya Hussain, Christine Brezden-Masley, Stephen Chia, et al.
Annals of Surgical Oncology|February 13, 2010
Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based seriesPauline T Truong, Mary Lesperance, Karen Hui Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancerIvo A Olivotto, Boon Chua, Sharon J Allan, et al.
Virchows Archiv : an International Journal of Pathology|October 29, 2009
Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five casesMelanie Seal, Christine Wilson, Gregory J Naus, et al.
Pharmaceutical Research|June 11, 2005
Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levelsDawn N Waterhouse, Tetyana Denyssevych, Norma Hudon, et al.
Breast Cancer Research and Treatment|April 30, 2008
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effectsHeather-Jane Au, Kamran Golmohammadi, Tallal Younis, et al.
The Oncologist|February 4, 2012
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancerLindsay Hedden, Susan O'Reilly, Caroline Lohrisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trialStephen Chia, Mark Clemons, Lee-Ann Martin, et al.
Health and Quality of Life Outcomes|December 3, 2013
Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6DPaulos Teckle, Helen McTaggart-Cowan, Kim Van der Hoek, et al.
Pageof 11